PRANDONI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.588
AS - Asia 4.601
EU - Europa 3.273
SA - Sud America 1.137
AF - Africa 963
OC - Oceania 101
Continente sconosciuto - Info sul continente non disponibili 43
Totale 29.706
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.115
SG - Singapore 1.464
HK - Hong Kong 1.058
BR - Brasile 813
CN - Cina 783
FI - Finlandia 483
DE - Germania 320
VN - Vietnam 318
SE - Svezia 294
UA - Ucraina 257
FR - Francia 253
IT - Italia 247
PL - Polonia 189
RU - Federazione Russa 166
GB - Regno Unito 159
AT - Austria 95
IE - Irlanda 74
TR - Turchia 65
AR - Argentina 64
NL - Olanda 58
IN - India 55
ZA - Sudafrica 51
MX - Messico 46
BG - Bulgaria 41
CA - Canada 41
EC - Ecuador 41
IQ - Iraq 41
CO - Colombia 40
ES - Italia 39
ID - Indonesia 39
PK - Pakistan 39
JO - Giordania 36
PE - Perù 36
TN - Tunisia 36
CI - Costa d'Avorio 35
JP - Giappone 35
UZ - Uzbekistan 35
DK - Danimarca 34
PH - Filippine 34
AO - Angola 33
CZ - Repubblica Ceca 33
KG - Kirghizistan 33
KR - Corea 33
AE - Emirati Arabi Uniti 32
AL - Albania 30
CH - Svizzera 30
GM - Gambi 30
IR - Iran 30
LC - Santa Lucia 30
KZ - Kazakistan 29
MG - Madagascar 29
LB - Libano 28
NO - Norvegia 28
SA - Arabia Saudita 28
TJ - Tagikistan 28
UG - Uganda 28
UY - Uruguay 28
AZ - Azerbaigian 27
BA - Bosnia-Erzegovina 27
CW - ???statistics.table.value.countryCode.CW??? 27
GF - Guiana Francese 27
GN - Guinea 27
GR - Grecia 27
LV - Lettonia 27
NZ - Nuova Zelanda 27
IL - Israele 26
LA - Repubblica Popolare Democratica del Laos 26
MK - Macedonia 26
RO - Romania 26
ZW - Zimbabwe 26
BB - Barbados 25
BE - Belgio 25
BY - Bielorussia 25
CY - Cipro 25
EE - Estonia 25
GA - Gabon 25
HR - Croazia 25
LY - Libia 25
MY - Malesia 25
NI - Nicaragua 25
PY - Paraguay 25
SO - Somalia 25
YT - Mayotte 25
AM - Armenia 24
BO - Bolivia 24
CD - Congo 24
DO - Repubblica Dominicana 24
KE - Kenya 24
MR - Mauritania 24
MU - Mauritius 24
PS - Palestinian Territory 24
PT - Portogallo 24
RE - Reunion 24
EG - Egitto 23
GH - Ghana 23
HU - Ungheria 23
IS - Islanda 23
JM - Giamaica 23
PR - Porto Rico 23
RS - Serbia 23
Totale 28.641
Salva come PNG Salva come JPEG
Città #
Fairfield 3.243
Woodbridge 2.096
Houston 1.561
Ashburn 1.423
Seattle 1.220
Wilmington 1.198
Ann Arbor 1.184
Jacksonville 1.182
Cambridge 1.060
Hong Kong 1.039
Chandler 816
Singapore 734
Princeton 550
Boardman 455
San Diego 323
Santa Clara 214
Nanjing 182
Roxbury 174
Des Moines 171
Medford 168
Helsinki 148
Bytom 143
Dong Ket 141
Beijing 140
Los Angeles 64
Ho Chi Minh City 60
Dublin 57
New York 55
Shenyang 52
São Paulo 50
Nanchang 47
Guangzhou 45
Nuremberg 44
Hebei 42
Jiaxing 41
London 39
Munich 39
Vienna 39
Buffalo 37
Hanoi 37
Norwalk 37
Amman 36
Chicago 35
Abidjan 33
Luanda 33
Padova 33
Redwood City 33
Sofia 31
Tashkent 31
Tianjin 31
Bishkek 30
Castries 30
Antananarivo 28
Kampala 28
Belo Horizonte 27
Conakry 27
Council Bluffs 26
Lima 26
Baku 25
Bridgetown 25
Dushanbe 25
Nouakchott 24
Willemstad 24
Hefei 23
Kinshasa 23
Libreville 23
Managua 23
Dakar 22
Harare 22
Kigali 22
Milan 22
Riga 22
Cayenne 21
Changsha 21
Montevideo 21
Vientiane 20
Accra 19
Cotonou 19
Dar es Salaam 19
Nairobi 19
Noumea 19
Rio de Janeiro 19
Andorra la Vella 18
Niamey 18
Ogden 18
Tirana 18
Tunis 18
Warsaw 18
Yerevan 18
Banjul 17
Ouagadougou 17
Panama City 17
San José 17
Guayaquil 16
Kharkiv 16
Lusaka 16
Maputo 16
Podgorica 16
Tallinn 16
Tripoli 16
Totale 21.696
Salva come PNG Salva come JPEG
Nome #
Outcomes in Neurosurgical Patients Who Develop Venous Thromboembolism: A Review of the RIETE Registry 374
Diagnostic Value of Measuring Platelet Von Willebrand Factor in Von Willebrand Disease. 212
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score 209
A venous thromboembolism risk assessment model for patients with Cushing’s syndrome 179
The incidence of venous thromboembolism in carriers of antithrombin, protein C or protein S deficiency associated with the HR2 haplotype of factor V: a family cohort study 159
The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience 157
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients 156
The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism 152
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. 150
A Prospective Cohort Study On Patients Treated With Anticoagulants For Cerebral Vein Thrombosis. 149
Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis: retrospective cohort study 148
Unexpectedly high recanalization rate in patients with pulmonary embolism treated with anticoagulants alone. 147
Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism 145
Low reproducibility of the diagnosis of subsegmental pulmonary embolism in symptomatic patients 144
Dabigatran antagonizes growth, cell-cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines 142
How to effectively manage the event of bleeding complications when using anticoagulants 139
An unusual finding of massive pulmonary embolism in a patient during treatment with high-dose ibuprofen 137
Risk factors, antithrombotic treatment and outcome in retinal vein occlusion: an age-related prospective cohort study 136
Acute venous thromboembolism after non-major orthopaedic surgery or post-traumatic limb immobilisation 135
Iliopsoas bursitis and femoral vein thrombosis complicating total hip arthroplasty in an elderly patient 134
Aspirin for preventing the recurrence of venous thromboembolism. 133
The post-thrombotic syndrome 132
Cancer as a risk factor for stroke in atrial fibrillation patients receiving long-term oral anticoagulant therapy 130
The impact of residual thrombosis on the long-term outcome of patients with deep venous thrombosis treated with conventional anticoagulation. 129
Fondaparinux in the initial and long-term treatment of venous thromboembolism 129
Silent pulmonary embolism in patients with proximal deep vein thrombosis in the lower limbs 129
Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry 128
Incidence of VTE in asymptomatic children with deficiencies of antithrombin, protein C, and protein S: a prospective cohort study 128
Thirty-day mortality rate in women with cancer and venous thromboembolism. Findings from the RIETE Registry 127
Accuracy of two newly described D-dimer tests in patients with suspected deep venous thrombosis. 126
Antithrombotic Therapy for VTE Disease 123
Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study 123
Factors Associated with elevated Pulmonary Arterial Pressure Levels on the Echocardiographic Assessment in Patients with Prior Pulmonary Embolism 122
A clinical prognostic model for the identification of low-risk patients with acute symptomatic pulmonary embolism and active cancer. 122
Cancer Screening in Unprovoked Venous Thromboembolism 121
Long-term use of vitamin K antagonists and incidence of cancer: a population-based study 120
Thrombolytic therapy and outcome of patients with an acute symptomatic pulmonary embolism 120
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: New scenarios and opportunities 120
Adherence to the novel oral anticoagulants: An unmet need 119
Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations. 118
Thrombophilia and the risk of the post-thrombotic syndrome: retrospective cohort observation. 118
Incidence of arterial embolism in patients on treatment with old and new anticoagulants for venous thromboembolism 118
A prospective study on cardiovascular events after acute pulmonary embolism. 117
Family history of venous thrombosis or sudden death as a risk factor for venous thromboembolism. 117
Factor V Leiden is associated with more distal location of deep vein thrombosis of the leg. 116
A prospective study on survival in cancer patients with and without venous thromboembolism 116
Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies 116
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis 115
Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds. 115
Treatment of venous thromboembolism: the single-drug approach 115
An international survey on isolated subsegmental pulmonary embolism. 115
Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. 114
Approach to Venous Thromboembolism in the Cancer Patient 114
Unsuspected pulmonary embolism in patients with cancer 114
Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism 113
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. 112
Thrombophilia as a predictor of persistent residual vein thrombosis 111
Venous thromboembolism in 2013: The advent of the novel oral anticoagulants 111
Thrombophilia and the risk of post-thrombotic syndrome: Retrospective cohort observation 111
Cancer and venous thromboembolism 110
Circulating microparticles in carriers of factor V Leiden with and without a history of venous thrombosis. 110
Superficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancer 110
Residual pulmonary obstruction and the risk of late complications in patients with pulmonary embolism 110
A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. 109
The treatment of cancer-associated venous thromboembolism in the era of the novel oral anticoagulants 109
Failure of old and new anticoagulants to prevent ischemic stroke in high-risk atrial fibrillation: a case report 108
Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update 107
Long-term therapy with low-molecular-weight heparin in cancer patients with venous thromboembolism 107
A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the upper extremity 107
Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial 106
Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. 106
Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial. 106
Clinical presentation and outcome of venous thromboembolism in COPD 105
D-Dimer testing as an adjunct to ultrasonography in patients with clinically suspected deep vein thrombosis: prospective cohort study. 104
THE LONG TERM CLINICAL COURSE OF ACUTE DEEP VEIN THROMBOSIS OF THE ARM: PROSPECTIVE COHORT STUDY 104
Superficial vein thrombosis: Risk factors, diagnosis, and treatment 104
“Thrombotic aura”: a case report 104
Role of D-dimer monitoring for the diagnosis of deep vein thrombosis in patients undergoing neurosurgery for brain tumor 104
Venous thromboembolism as first manifestation of cancer. 103
Can causes of false-normal D-dimer test [SimpliRED(R)] results be identified? 103
Thrombosis as a harbinger of cancer 103
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism 103
Residual vein thrombosis and trans-popliteal reflux in patients with and without the post-thrombotic syndrome. 103
Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. 103
Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. 102
Cancer and venous thromboembolism 102
A family with an abnormal protein C and a thrombotic tendency. 102
Physicians' compliance with the Padua Prediction Score for preventing venous thromboembolism among hospitalized medical patients. 102
Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. 102
Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. 101
Apixaban for Extended Treatment of Venous Thromboembolism 101
Optimal duration of anticoagulation: Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests 101
Validation of a model for identification of patients at intermediate to high risk for complications associated with acute symptomatic pulmonary embolism 101
Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. 101
Pulmonary embolism: Epidemiology and registries 101
The risk of arterial thrombosis in carriers of natural coagulation inhibitors: a prospective family cohort study 101
Diagnosis of recurrent deep vein thrombosis. 100
Venous thromboembolism in patients with intracranial haemorrhage 100
Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism: findings from the RIETE registry 100
Venous thromboembolism in immobilized patients with dementia. Findings from the RIETE registry. 100
Totale 12.246
Salva come PNG Salva come JPEG
Categoria #
all - tutte 92.930
article - articoli 91.624
book - libri 429
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 479
Totale 185.462
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.814 0 0 38 304 154 292 90 325 519 306 418 368
2021/20223.750 103 349 510 248 220 195 127 431 262 90 433 782
2022/20232.033 618 111 27 196 406 245 4 97 197 14 83 35
2023/20241.032 34 124 95 76 94 95 67 30 48 34 184 151
2024/20254.779 17 299 260 152 763 76 206 317 488 197 781 1.223
2025/20264.693 492 2.230 1.971 0 0 0 0 0 0 0 0 0
Totale 29.863